Synaptogenix Inc (SNPX)

[SF Wolf]

Neurotrope Bioscience Concludes Patient Dosing and Monitoring in its 148 Patient Phase 2 Clinical Trial of Moderate to Severe Alzheimer's Dementia
Top-line efficacy data is expected to be announced in April 2017

News provided by
Neurotrope, Inc.
Feb 28, 2017, 08:30 ET


"We are very pleased with the execution of the study.  It took only about 13 months from initiation of randomization of the study to completion the last patient visit," Dr. Susanne Wilke, Chief Executive Officer of Neurotrope stated.

"The multi-modal efficacy of bryostatin-1 was extensively studied in both animal models and Expanded Access patients with advanced Alzheimer's dementia. We believe that these studies demonstrated bryostatin's potential to actually improve cognitive functions, not simply slow the rate of cognitive decline," stated Dr. Daniel Alkon, President and Chief Scientific Officer of Neurotrope. "
http://www.prnewswire.com/news-releases/neurotrope-bioscience-concludes-patient-dosing-and-monitoring-in-its-148-patient-phase-2-clinical-trial-of-moderate-to-severe-alzheimers-dementia-300414678.html